Monomer and multimeric Anti-hbv agents

A prodrug, unsaturated technology, used in antiviral agents, pharmaceutical formulations, active ingredients of boron compounds, etc., can solve the problems of affecting drug resistance, inability to provide, high remission rate, etc.

Pending Publication Date: 2021-07-23
EMORY UNIVERSITY
View PDF72 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

All of these drugs are very effective in reducing viral load, but none of them provide high remission rates
Furthermore, their impact may be limited by drug resistance, inefficiency and tolerability issues

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Monomer and multimeric Anti-hbv agents
  • Monomer and multimeric Anti-hbv agents
  • Monomer and multimeric Anti-hbv agents

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment

[0692] Specific compounds representative of the invention were prepared according to the following examples and reaction sequences; the examples and figures depicting the reaction sequences are provided by way of illustration to aid in the understanding of the invention and should not be construed as limiting in any way the following The invention is set forth in the claims of . Compounds of the present invention may also be used as intermediates in subsequent examples to yield additional compounds of the present invention. There is no need to try to optimize the yield obtained in any reaction. Those skilled in the art will know how to increase such yields by routine changes in reaction times, temperatures, solvents and / or reagents.

[0693] Anhydrous solvents were purchased from Aldrich Chemicals, Inc. (Milwaukee, WI) and EMD Chemicals, Inc. (Gibbstown, NJ). Reagents were purchased from commercial sources. Unless otherwise stated, materials used in the examples were obtain...

Embodiment 1

[0695]

[0696] Scenario 19

[0697] Reagents and conditions: a) i) benzyl 3-oxobutyrate, AcOH, iPrOH, piperidine, 50°C, 1h;

[0698] ii) pyridine-2-carboxamidine hydrochloride, 125°C, 3 days; b) i) NBS, AcOH, DCE, 50°C, 30 min; ii) morpholine, Et 3 N, DMF, RT, 18h; c)H 2 , Pd / C, EtOH, RT, 1h; d) NaI, Na 2 CO 3 , oxone, MeOH / H 2 O, 1 h, RT; e) CbzCl, KHMDS, THF, -78°C to RT, 15 h; f) ethynylcyclopropane, PdCl 2 (PPh 3 ) 2 , CuI, Et 3 N, DMF, RT, 4h; g) BCl 3 , DCM, -78°C, 3h.

[0699] Benzyl 4-(2-chloro-4-fluorophenyl)-6-methyl-2-(pyridin-2-yl)-1,4-dihydropyrimidine-5-carboxylate (2)

[0700] To a suspension of 2-chloro-4-fluorobenzaldehyde (6 g, 37.8 mmol), piperidine (3 mL), acetic acid (1 mL) in dry isopropanol (60 mL) was added benzyl 3-oxobutyrate (10.9 g, 56.8 mmol). The mixture was heated at 50°C for 1 hour, then pyridine-2-carboxamidine hydrochloride (5.96 g, 37.8 mmol) was added. The resulting solution was kept at 125°C for 3 days and then concentrat...

Embodiment 2

[0976] Cytotoxicity assay

[0977] As previously described (see Schinazi R.F., Sommadossi J.-P., Saalmann V., Cannon D.L., Xie M.-Y., Hart G.C., Smith G.A. & Hahn E.F. Antimicrob. Agents Chemother. 1990, 34, 1061-67) , the toxicity of compounds was assessed in Vero, human PBM, CEM (human lymphoblastoid), MT-2 and HepG2 cells. Cycloheximide was included as a positive cytotoxicity control, and untreated solvent-exposed cells were included as a negative control. Cytotoxicity ICs were obtained from concentration-response curves using the previously described median efficient method 50 (See Chou T.-C. & Talalay P. Adv. Enzyme Regul. 1984, 22, 27-55; Belen'kii M.S. & Schinazi R.F. Antiviral Res. 1994, 25, 1-11). The results are shown in Table 1 below:

[0978] Table 1

[0979] Cytotoxicity, CC 50 , μM (% inhibition)

[0980]

[0981]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
particle sizeaaaaaaaaaa
Login to view more

Abstract

The present invention is directed to compounds, compositions and methods for preventing, treating or curing hepatitis B (HBV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment, prevention or eradication of HBV infection.

Description

technical field [0001] The present invention relates to compounds, methods and compositions for preventing, treating and / or curing hepatitis B virus (HBV) infection. More specifically, the present invention specifically describes substituted aromatic / heteroaromatic compounds, pharmaceutically acceptable salts or other derivatives thereof, and their use as monomeric or linked multimeric agents in the treatment or cure of HBV infection. use in. Background technique [0002] Hepatitis B virus (HBV) causes serious human health problems and is the second largest cause of human cancer after tobacco. The mechanism by which HBV induces cancer is unclear. It has been speculated that it may trigger tumor development directly or indirectly through chronic inflammation, cirrhosis, and infection-related cellular regeneration. [0003] During the incubation period, the host is usually unaware of the infection, and after an incubation period of 2 to 6 months, HBV infection can cause acu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D403/12C07D403/14C07D417/14A61K31/4025A61K31/454A61K31/427A61K31/519A61K31/4192A61P31/20
CPCA61K31/4025A61K31/4192A61K31/454A61K31/519A61P31/20C07D403/14C07D417/14C07D207/416C07D207/22C07D487/04C07D471/08C07D295/125C07D417/04A61K45/06A61K31/506A61K31/407A61K31/5377A61K31/437A61K31/69A61K31/661A61K47/55A61K2300/00C07D403/12C07D471/04C07D249/04C07D401/04C07D401/14C07D471/18C07D498/18
Inventor 雷蒙德·F·斯基那兹弗兰克·安布拉尔布莱恩·考克斯陈彻勒达·巴赛特
Owner EMORY UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products